This is a preview of subscription content, log in via an institution to check access.
References
Murasaki M, Miura S. Long term-treatment of a new atypical neuroleptic, SM-9018 on patients with schizophrenia. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 201
Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol. Rinsho Hyoka 1997; 24 (2–3): 159–205
Kudo Y, Nakajima T, Saito M, et al. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia: a comparative double-blind study with mosapramine HCl. Rinsho Hyoka 1997; 24 (2–3): 207–48
Kato T, Hirose A, Ohno Y, et al. Binding profile of SM-9018, a novel antipsychotic candidate. Jap J Pharmacol 1990 Dec; 54: 478–81
Ishida K, Ohno Y, Okada K, et al. Effects of SM-9018, a potential atypical antipsychotic, on electrically-evoked 3H-acetylcholine release in rat striatal slices. Jap J Pharmacol 1993; 61 Suppl. I: 277P
Maruoka Y, Ohno Y, Kato T, et al. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats. Jap J Pharmacol 1993 Aug; 62: 419–22
Rights and permissions
About this article
Cite this article
Perospirone. Drugs R&D 2, 142–143 (1999). https://doi.org/10.2165/00126839-199902020-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902020-00016